Waddill William D. — SEC Form 4 filings
SEC reporting owner CIK 1553338. 24 Form 4 filings on record with FilingPulse; latest filed 2026-06-25.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2024-01-16 to 2026-06-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 20 legs across 15 filings — 127,771 shares, $8,538,518 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 20,000 shares @ $83.68 ($1,673,600) in Protagonist Therapeutics, Inc, filed 2026-02-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | Director | 14 | — | 13 legs · 107,975 sh · $7,658,056 | 24 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | Director | 5 | — | 7 legs · 19,796 sh · $880,462 | 2 |
| Annexon, Inc. (ANNX) | Director | 3 | — | — | 3 |
| Turnstone Biologics Corp. (TSBX) | Director | 2 | — | — | 2 |
Form 4 filings — Waddill William D.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-25 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 9,000 @ $16.54 · Sale (S): 9,000 @ $117.94 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 3,000 @ $11.80 · Option exercise (M): 6,000 @ $16.54 · Sale (S): 9,000 @ $107.68 · Option exercise (M): 3,000 (derivative) @ $0 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 9,000 @ $11.80 · Sale (S): 9,000 @ $99.64 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 20,000 @ $8.31 · Sale (S): 20,000 @ $83.68 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 2,695 @ $0 · Grant/award (A): 3,762 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | Sale (S): 2,416 @ $66.66 · Sale (S): 5,451 @ $68.01 · Sale (S): 500 @ $68.53 | EDGAR |
| 2025-12-18 | 4 | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-10-14 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 12,000 @ $6.98 · Sale (S): 4,000 @ $69.25 · Sale (S): 8,000 @ $87.81 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Protagonist Therapeutics, Inc (PTGX) | Sale (S): 4,000 @ $64.25 | EDGAR |
| 2025-08-29 | 4 | Protagonist Therapeutics, Inc (PTGX) | Sale (S): 4,000 @ $59.25 | EDGAR |
| 2025-06-09 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Protagonist Therapeutics, Inc (PTGX) | Sale (S): 4,000 @ $54.25 | EDGAR |
| 2025-01-06 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 5,130 @ $0 · Grant/award (A): 6,584 (derivative) @ $0 | EDGAR |
| 2024-12-20 | 4 | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | Grant/award (A): 16,733 @ $22.99 | EDGAR |
| 2024-12-18 | 4 | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | Sale (S): 3,748 @ $21.90 · Sale (S): 3,747 @ $22.04 | EDGAR |
| 2024-09-12 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 8,000 @ $12.88 · Sale (S): 8,000 @ $45 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 8,000 @ $12.88 · Sale (S): 8,000 @ $40 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Turnstone Biologics Corp. (TSBX) | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 8,000 @ $12.88 · Sale (S): 8,000 @ $35 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2024-04-16 | 4 | Turnstone Biologics Corp. (TSBX) | Grant/award (A): 25,540 (derivative) @ $0 | EDGAR |
| 2024-03-01 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 12,975 @ $6.09 · Sale (S): 12,975 @ $31.34 · Option exercise (M): 12,975 (derivative) @ $0 | EDGAR |
| 2024-01-16 | 4 | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | Sale (S): 2,634 @ $37.81 · Sale (S): 1,300 @ $38.59 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1553338 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →